JLE

Bulletin du Cancer

MENU

High dose rate brachytherapy boost for primary nasopharyngeal carcinoma: preliminary results of an ongoing prospective study Volume 92, numéro 7, Juillet - Août 2005

Auteurs
Department of Radiation Oncology, Consultant Radiation Oncologist, 118, Tata Memorial Hospital, Dr Ernest Borges Marg, Parel, Mumbai 400012, India, Department of Radiation Oncology, ACTREC, Navi Mumbai, India

Background: The exact role of brachytherapy boost in primary nasopharyngeal carcinoma (NPC) is yet to be completely elucidated. We conducted this prospective study to evaluate outcome of patients with NPC treated with high dose rate brachytherapy (HDR-BT) boost, following radical external beam radiotherapy (EBRT) with or without chemotherapy. Methods: Between 1998 and 2003, 10 patients of primary NPC were prospectively considered for HDR-BT boost. Median EBRT dose was 66 Gy (range: 60-70 Gy). Median HDR-BT boost dose was 12 Gy (range: 5-14 Gy) given in 1-4 fractions. Results: At a median follow-up of 28 months (range: 5-66 months), the local control rate was 90%. Two patients developed distant metastases and one patient developed a second primary in the lower alveolus. The 3-year disease free survival rate was 60%. Grade III mucositis developed in 2 (20%) patients. Conclusions: HDR-BT is an efficacious boost modality with acceptable morbidity in selected patients with NPC.